{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:17:14Z","timestamp":1791227834945,"version":"4.1.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/wnf.0b013e31825f77b9","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T09:56:14Z","timestamp":1342518974000},"page":"174-181","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa\u2013Undertreated Parkinson Disease"],"prefix":"10.1097","volume":"35","author":[{"given":"Yoshikuni","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadako","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Kagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Sarashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.V.","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinsons disease as a clinical syndrome.","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinsons disease: results of a double-blind, placebo-controlled, parallel-group study.","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinsons disease: a double blind, placebo controlled, randomised, multicentre study.","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.22450","article-title":"Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinsons disease.","volume":"24","year":"2009","journal-title":"Mov Disord"},{"issue":"6","key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale.","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":". Assessment of dose proportionality: report from the statisticians in the pharmaceutical industrypharmacokinetic UK joint working party.","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf J"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e31825f77b9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:15:03Z","timestamp":1620962103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201207000-00004"}},"subtitle":["A Double-Blind, Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31825f77b9","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}